Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...
AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...
Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...
Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.
Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.
In recent developments, Recursion Pharmaceuticals unveiled advances in its AI platform for drug discovery, forming collaborations with major pharmaceutical groups including Sanofi, Roche/Genentech, ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
The ability to respond to changing surroundings was once considered exclusive to complex living organisms. Then came ...
Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
With AI advancements upending the role of senior executives, the question is what the C-suite transformation should look like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback